Form 4: Entrada Therapeutics CFO Kory James Wentworth Reports Stock Option Exercise and Resulting Share Ownership

Kory James Wentworth, CFO of Entrada Therapeutics, exercised stock options and acquired 11,134 shares of common stock at $2.1 per share on April 3, 2025, according to a Form 4 filing.

Summary

• On April 3, 2025, Kory James Wentworth, the Chief Financial Officer of Entrada Therapeutics, Inc. (TRDA), executed a transaction involving the company's stock.
• Wentworth exercised stock options, acquiring 11,134 shares of common stock at a price of $2.1 per share.
• Following this transaction, Wentworth directly owns 120,670 shares of Entrada Therapeutics common stock.
• Wentworth also owns 20,023 derivative securities.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a routine disclosure of an insider transaction. The exercise of options is neither particularly positive nor negative on its own.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, trade their company's stock. These filings provide transparency to the market regarding the actions of those with privileged information.

Stakeholder Impact

• The transaction could have a minor impact on shareholders by slightly increasing the number of outstanding shares.

Key Dates

Keywords

Entrada Therapeutics, TRDA, Kory James Wentworth, CFO, stock options, Form 4, beneficial ownership, securities, acquisition